Overall, this work indicates that the deletion of miR-33 in hepatocytes is sufficient to regulate several pathways altered throughout the development of MASL/MASH/HCC, impeding the progression of the disease. This evidence concerns the gene MAS1L and hepatocellular carcinoma.